drugset / Trial / NCT07108699
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
Timeline
- Start
- 2025-08-13
- Primary completion
- 2026-08-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK39004 | Unknown | 0.75 mg | Inhaled |
| Subject | HSK39004 | Unknown | 1.5 mg | Inhaled |